Adenosinergic Pathway in Parkinson’s Disease: Recent Advances and Therapeutic Perspective

Zhao, Yuan; Liu, Xin; Yang, Guofeng

doi:10.1007/s12035-023-03257-3

Cited by 3 publications

(2 citation statements)

References 168 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In PD, dopamine production is impaired because of degeneration of the substantia nigra [ 2 , 3 , 4 , 5 , 6 ]. Precursors of dopamine are the most commonly used pharmaceuticals, and L-dihydroxyphenylalanine (L-dopa) is the most widely used [ 7 ]. When pharmacological treatment ceases to control symptoms adequately, deep brain stimulation (DBS) is used to mitigate motor symptoms and decrease drug dosage.…”

Section: Introductionmentioning

confidence: 99%

Effect of 12-Week BMI-Based Vitamin D3 Supplementation in Parkinson’s Disease with Deep Brain Stimulation on Physical Performance, Inflammation, and Vitamin D Metabolites

Bytowska,

Korewo-Labelle,

Berezka

et al. 2023

IJMS

View full text Add to dashboard Cite

Parkinson’s disease (PD) is the second most common neurodegenerative disease. To manage motor symptoms not controlled adequately with medication, deep brain stimulation (DBS) is used. PD patients often manifest vitamin D deficiency, which may be connected with a higher risk of falls. We administered a 12-week vitamin D3 supplementation based on BMI (with higher doses given to patients with higher BMI) to investigate its effects on physical performance and inflammation status in PD patients with DBS. Patients were randomly divided into two groups: treated with vitamin D3 (VitD, n = 13), and supplemented with vegetable oil as the placebo group (PL, n = 16). Patients underwent functional tests to assess their physical performance three times during this study. The serum 25(OH)D3 concentration increased to the recommended level of 30 ng/mL in the VitD group, and a significant elevation in vitamin D metabolites in this group was found. We observed significant improvement in the Up and Go and the 6 MWT in the VitD group. In inflammation status, we noticed a trend toward a decrease in the VitD group. To conclude, achieving the optimal serum 25(OH)D3 concentration is associated with better functional test performance and consequently may have a positive impact on reducing falling risk in PD.

show abstract

Section: Introductionmentioning

confidence: 99%

Effect of 12-Week BMI-Based Vitamin D3 Supplementation in Parkinson’s Disease with Deep Brain Stimulation on Physical Performance, Inflammation, and Vitamin D Metabolites

Bytowska,

Korewo-Labelle,

Berezka

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…In this disease, cannabinoid-based therapies may serve to delay disease progression, but also to alleviate specific parkinsonian symptoms [ 3 , 4 ]. Thus, preclinical studies have demonstrated that modulating the cannabinoid receptor type 1 (CB 1 ) may serve for reducing parkinsonian signs such as bradykinesia and immobility [ 5 ], tremor [ 6 ] and/or L-DOPA-induced dyskinesia [ 7 ], This can occur even combined in combination with other agents, such adenosine receptor ligands [ 8 , 9 ] such as these receptors may form heteromers with the CB 1 receptor resulting in possible synergic effects at a pharmacological level [ 10 , 11 ]. Such a combination between CB 1 and adenosine receptor ligands has been already investigated in pathological conditions other than PD [ 12 , 13 ].…”

Section: Introductionmentioning

confidence: 99%

The Cannabigerol Derivative VCE-003.2 Exerts Therapeutic Effects in 6-Hydroxydopamine-Lesioned Mice: Comparison with The Classic Dopaminergic Replacement Therapy

Rodríguez-Carreiro,

Navarro,

Muñoz

et al. 2023

Brain Sciences

View full text Add to dashboard Cite

(1) Background: A cannabigerol aminoquinone derivative, so-called VCE-003.2, has been found to behave as a neuroprotective agent (administered both i.p. and orally) in different experimental models of Parkinson’s disease (PD) in mice. These effects were exerted through mechanisms that involved the activation of a regulatory site within the peroxisome proliferator-activated receptor-γ (PPAR-γ). (2) Methods: We are now interested in comparing such neuroprotective potential of VCE-003.2, orally administered, with the effect of the classic dopaminergic replacement therapy with L-DOPA/benserazide in similar conditions, using 6-hydroxydopamine-lesioned mice. (3) Results: The oral administration of VCE-003.2 during 14 days at the dose of 20 mg/kg improved, as expected, the neurological status (measured in motor tests) in these mice. This correlated with a preservation of TH-labelled neurons in the substantia nigra. By contrast, the treatment with L-DOPA/benserazide (during 7 days at 2 mg/kg) was significantly less active in these experimental conditions, in concordance with their profile as a mere symptom-alleviating agent. (4) Conclusions: Our results confirmed again the therapeutic profile of VCE-003.2 in experimental PD and revealed a different and more relevant effect, as a disease modifier, compared to the classic symptom-alleviating L-DOPA treatment. This reinforces the interest in VCE-003.2 for a future clinical development in this disease.

show abstract

Human Glial Cells as Innovative Targets for the Therapy of Central Nervous System Pathologies

Magni,

Riboldi,

Ceruti

2024

Cells

View full text Add to dashboard Cite

In vitro and preclinical in vivo research in the last 35 years has clearly highlighted the crucial physiopathological role of glial cells, namely astrocytes/microglia/oligodendrocytes and satellite glial cells/Schwann cells in the central and peripheral nervous system, respectively. Several possible pharmacological targets to various neurodegenerative disorders and painful conditions have therefore been successfully identified, including receptors and enzymes, and mediators of neuroinflammation. However, the translation of these promising data to a clinical setting is often hampered by both technical and biological difficulties, making it necessary to perform experiments on human cells and models of the various diseases. In this review we will, therefore, summarize the most relevant data on the contribution of glial cells to human pathologies and on their possible pharmacological modulation based on data obtained in post-mortem tissues and in iPSC-derived human brain cells and organoids. The possibility of an in vivo visualization of glia reaction to neuroinflammation in patients will be also discussed.

show abstract

Adenosinergic Pathway in Parkinson’s Disease: Recent Advances and Therapeutic Perspective

Cited by 3 publications

References 168 publications

Effect of 12-Week BMI-Based Vitamin D3 Supplementation in Parkinson’s Disease with Deep Brain Stimulation on Physical Performance, Inflammation, and Vitamin D Metabolites

Effect of 12-Week BMI-Based Vitamin D3 Supplementation in Parkinson’s Disease with Deep Brain Stimulation on Physical Performance, Inflammation, and Vitamin D Metabolites

The Cannabigerol Derivative VCE-003.2 Exerts Therapeutic Effects in 6-Hydroxydopamine-Lesioned Mice: Comparison with The Classic Dopaminergic Replacement Therapy

Human Glial Cells as Innovative Targets for the Therapy of Central Nervous System Pathologies

Contact Info

Product

Resources

About